Patients saw 30 percent reduced risk of adverse events after two years of follow up. Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy following the insertion of a coronary stent.
Pharma News
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.











